CXCL10 News and Research

RSS

How the common cold can provide protection against COVID-19

In a recent study, researchers found that prior infection with the rhinovirus can provide a more effective immune response against SARS-CoV-2 infection.

17 Jun 2021

Eldelumab and Fenofibrate show potential for COVID-19

In a new study posted to the medRxiv* preprint server, researchers from the University of Pittsburgh and Barrow Neurological Institute report the results of their analysis of several RNA-Seq studies and used computational approaches to discover potential drugs against COVID-19.

10 Jun 2021

Researchers identify a bacterium with anti-SARS-CoV-2 activity in vitro: Dolosigranulum pigrum

As intensive efforts are on to counter the virus, a new study by an international team of researchers reports the unexpected success of a bacterium in modulating the immune response in the airway and protecting the cells against infection with this virus.

7 Jun 2021

Could sustained inflammation following mild to moderate COVID-19 be a driver of long COVID?

A new study describes the discovery of sustained though low-level rises in inflammatory mediators and immune cells, as well as the loss of some subsets of naïve un-activated cells. This may indicate a widespread though muted immune-mediated inflammatory response in these patients.

7 Jun 2021

A potential treatment to prevent obesity-related liver damage

One of the especially dangerous health risks of being extremely overweight occurs when an obese person begins to accumulate fat in their liver.

18 May 2021

What happens in the first few days of SARS-CoV-2 infection?

New research, published in PLOS Biology, has evaluated SARS-CoV-2 infection in primary cultures of well-differentiated cells to determine how the virus affects the body and how the infection starts. Answers to these questions are essential to forming a general understanding of viral pathogenesis, which helps us develop effective prevention and treatment strategies for COVID-19.

4 May 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

Male fetuses impair the maternal and placental immune response to SARS-CoV-2 infection in pregnancy, finds study

The ongoing COVID-19 pandemic, caused by SARS-CoV-2, is now established to be more likely to lead to symptomatic and serious illness in males relative to females. This may extend as far back as pregnancy, suggests a recent study.

31 Mar 2021

Alzheimer’s symptoms linked to COVID-induced brain injury

New research shows further evidence between COVID-19 infection and the development of long-term neurological symptoms. The findings found COVID-induced neuroinflammation and microvascular injury contributed to dementia-like symptoms. However, they also found evidence indicating a low possibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly invading the brain.

24 Mar 2021

COVID-19 and lung cancer have a common pathway, say researchers

A new preprint on the bioRxiv* server describes the common features COVID-19 shares with lung cancer.

19 Feb 2021

RIG-1-like receptors may play dominant role in suppressing SARS-CoV-2 infection

A new study by researchers at the University of Connecticut Health Center, USA, reports the crucial nature of the pathogen pattern recognition receptor (PRRs), especially the two RLRs, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), in triggering host cell immune responses within the cell. The RLRs are viral RNA sensors.

15 Feb 2021

SARS-CoV-2 RNA in blood serum could predict COVID-19 mortality

Researchers find that the presence of SARS-CoV-2's genetic material in the serum of positive patients could be a sturdy biomarker for predicting COVID-19-related mortality.

18 Jan 2021

Combination therapy found to be effective against treatment-resistant hepatocellular carcinoma

A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital.

30 Nov 2020

HIV alters SARS-CoV-2 immune response without affecting COVID-19 symptoms or outcomes

In a preprint paper published on the medRxiv server, a team of researchers from various institutions in South Africa, the UK, and Europe discuss how they determined the impact of HIV on the COVID-19 immune response in KwaZulu-Natal, South Africa, which is an area with very high HIV prevalence.

26 Nov 2020

Favorable clinical outcome for ivermectin in COVID-19 animal model

A team of researchers at the Institut Pasteur in France has found that ivermectin prevented clinical deterioration in infected animals. The drug also reduced the inflammatory cytokines, interleukin-6 and 10 (IL-6 and IL-10) in lung tissue, which leads to more favorable clinical outcomes in treated animals.

23 Nov 2020

SARS-CoV-2 suppresses ACE2 activity in COVID-19 patients

A recent study conducted by a team of international scientists has revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19), suppresses the expression and function of human angiotensin-converting enzyme 2 (ACE2) and induces the expression of interferon-stimulated genes at the initial phase of infection. The study is currently available on the bioRxiv* preprint server.

20 Nov 2020

Myeloid cells can suppress immune response, promote brain metastasis

Scientists have long believed that the brain protects itself from an aggressive immune response to keep down inflammation. However, that evolutionary control may work against it when a cancer cell attempts to spread to the brain, researchers at the University of Notre Dame have discovered.

27 Oct 2020

Characterization of prognostic markers to predict COVID-19 severity

A team of scientists from the United Kingdom has revealed that markers of endothelial cell injury are associated with severe and fatal outcome of coronavirus disease 2019 (COVID-19). The study is currently available on the medRxiv* preprint server.

14 Oct 2020

SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19

A new study by a large team of Spanish researchers and published on the preprint server medRxiv* in August 2020 reports that the presence of viral RNA in the blood is a useful marker of impending acute disease and can help triage COVID-19 disease patients who will require hospital care.

1 Sep 2020

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on its ability to infect new host cells following its replication and release from infected cells. This pivots on its ability to bind to cell surface receptors like the ACE2 enzyme.

3 Aug 2020